Heartfelt VC is Europe's dedicated 'first cheque' fund, writing €100–400k pre-seed checks into exceptional founders building transformative companies across Europe and the US. Their mandate is explicitly 0-to-1: help founders achieve product-market fit, investing solo or alongside other early backers, with follow-on participation in subsequent rounds. Backed by Axel Springer and Porsche as corporate anchor investors, they have deployed into 300+ startups and maintain an active, sizeable Life Sciences AI cluster — Kiin Bio (OS for drug discovery), TriasBio (LLM for RNA expression), Misogi Labs (AI copilot for preclinical R&D), Genie TechBio (AI bioinformatician), Herlab (protein strain development), Implexis (self-driving drug formulation labs) — signalling genuine thesis alignment with computational biology and AI-for-drug-discovery rather than token life sciences exposure.

• Founder quality is the primary criterion — 'exceptional founders' language dominates all copy; background, domain credibility, and rare cross-disciplinary edge are scored hard at the first-call stage • Transformative company potential: they back 0-to-1 technological discontinuities, not incremental SaaS; the portfolio spans nuclear fusion, DNA-level drug discovery, and GPS-denied navigation, confirming tolerance for hard science • EU/US geography: Europe-based founding team is expected; their anchor investors (Axel Springer, Porsche) want corporate-Europe deal flow, so EU location is a commercial as well as eligibility signal • Pitch deck quality: the form's single file upload (deck) is the primary first-filter artefact — VC-tailored, concise, covering problem/solution/market/team/ask; the SEMIA grant deck format is a known killer • One-sentence description: explicitly required on the form — must be crisp, differentiated, and investor-language, not grant-language • Problem/opportunity + solution: the form limits this to 'a few sentences' — forces prioritisation; reviewers look for clarity of thinking, not comprehensiveness • Technology disclosure: form asked explicitly whether hardware/software and which technologies — precision here signals depth (name ESM-2, ECFP4, RF classifier, Platinum benchmark) • Business model: must state a plausible path to revenue (API licensing, pilot-to-SaaS, pharma partnerships) • Incorporation status: asked explicitly — 'not yet incorporated' is a soft flag at this ticket size; French SASU registration is straightforward and removes friction • Prior dilutive capital: full disclosure required (equity, SAFEs, loans including F&F) • Solo founder: form asks 'how many founders?' — portfolio shows they fund solos but multi-founder teams score higher on resilience; a named scientific advisor from Paris-Saclay would help • Network referrals: form includes 'who else should we invest in from your network?' — a warm intro from a Heartfelt portfolio company (e.g. Kiin Bio, TriasBio) would substantially accelerate the process

Heartfelt's 300+ portfolio features a clearly intentional Life Sciences AI cluster: Kiin Bio (OS for drug discovery), TriasBio (LLM for RNA expression), Misogi Labs (AI copilot for preclinical R&D teams), Genie TechBio (AI bioinformatician), Herlab (protein strain development), Implexis (self-driving labs for drug formulation), Chainreactor (bioreactors), Yendou (clinical trial execution layer), and Cori Clinical (AI platform for clinical trial backoffice). The archetype across this cluster is: solo or small founding team (1–3 people), deep technical background in biology or ML or both, novel AI/LLM application to a drug discovery or lab automation pain point, pre-revenue or very early revenue, EU-based. TriasBio (LLM for RNA expression) and Kiin Bio (OS for drug discovery) are the closest structural analogues to Eniola's venture and should be referenced as peer companies on any call. Named marquee companies from the main page — N26, DeepL, Colossyan, Greenlyte, Qualifyze — all became category leaders, confirming Heartfelt rewards bold category-defining positioning over modest framing.

The platonic ideal Heartfelt applicant is a technically exceptional founder — often solo — with rare cross-disciplinary credibility (e.g., biology + ML, pharma + software engineering) attacking a large life sciences vertical where incumbent tools are constrained by expensive or unavailable data, with a working proof-of-concept that de-risks the core technical claim and a named European pharma/biotech pilot in progress. They are EU-based, pre-Series A, can articulate a crisp zero-to-one inflection that the €100–400k Heartfelt check unlocks, and bring a network strong enough to refer other exceptional founders on the application form.